Compugen presents immuno-oncology pipeline update, targets COM701 interim analysis in Q1 2027
CGEN•Compugen expects its $117.5 million cash balance as of September 30, 2026, to fund operations into 2029, and projects an interim analysis of its COM701 trial in the first quarter of 2027. Its licensing agreements could provide up to $953 million in additional milestone payments.
1. Pipeline and cash update
Compugen said its cash balance was $117.5 million as of September 30, 2026, and expects it to fund operations into 2029. An interim analysis of the COM701 MAIA-ovarian maintenance therapy trial is projected for the first quarter of 2027.
2. Partnered programs
AstraZeneca's rilvegostomig program spans 12 Phase 3 trials, with ARTEMIDE-Biliary01 data anticipated in the second half of 2027. Rilvegostomig could generate up to $195 million in additional milestone payments and tiered royalties up to mid-single digits. Compugen's GS-0321 licensing agreement with Gilead offers up to $758 million in additional milestones, with tiered royalties ranging from single digits to low double digits.
